A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome

Project: Research project

Project Details

StatusActive
Effective start/end date4/25/19 → 8/31/50

Funding

  • ArQule, Inc.